Stereochemistry | RACEMIC |
Molecular Formula | C16H16ClNO3.ClH |
Molecular Weight | 342.217 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1=CC=C(C=C1)C2CNCCC3=C(Cl)C(O)=C(O)C=C23
InChI
InChIKey=NLMPGIXLXSPNFS-UHFFFAOYSA-N
InChI=1S/C16H16ClNO3.ClH/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;/h1-4,7,13,18-21H,5-6,8H2;1H
Molecular Formula | C16H16ClNO3 |
Molecular Weight | 305.756 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fenoldopam (marketed under the brand name Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. Fenoldopam Mesylate Injection, USP is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.
CNS Activity
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
Adults: Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous infusion.
Dosing can be increased in increments of 0.05 to 0.1 mcg/kg/minute
every 15 minutes or longer until target blood pressure is reached.
Dilute prior to administration
Pediatrics: Initiate dosing at 0.2 mcg/kg/minute by continuous infusion
and titrate dose by 0.3 to 0.5 mcg/kg/min every 20-30 minutes to a
maximum dose of 0.8 mcg/kg/minute
Route of Administration:
Intravenous